12/05/2024
4:17 PM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
11/13/2024
8:04 AM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
8:10 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
4:00 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2024
6:23 AM | Adaptimmune Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/12/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
08/02/2024
6:00 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/16/2024
3:30 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:39 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:14 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2024
6:34 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/22/2024
4:15 PM | Adaptimmune Therapeutics (Filer)
| Form ARS | |
04/12/2024
7:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2024
7:00 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/02/2024
7:38 PM | Adaptimmune Therapeutics (Subject)
New Enterprise Associates 14, L.P. (Filed by)
| Form SC 13D/A | |
04/01/2024
7:01 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
03/26/2024
10:59 AM | Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SC 13G/A | |
03/26/2024
11:00 AM | Adaptimmune Therapeutics (Issuer)
EcoR1 Capital, LLC (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/06/2024
6:12 AM | Adaptimmune Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2024
7:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/31/2024
4:07 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/30/2024
4:26 PM | Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SC 13G | |
01/29/2024
10:52 AM | Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
| Form SC 13G/A | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:30 PM | Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:31 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:00 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
Wood Gavin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:01 PM | Adaptimmune Therapeutics (Issuer)
TAYTON-MARTIN HELEN KATRINA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:02 PM | Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:02 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:03 PM | Adaptimmune Therapeutics (Issuer)
Hege Kristen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:03 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2024
4:06 PM | Adaptimmune Therapeutics (Issuer)
Behbahani Ali (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/04/2024
6:46 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Genesis leading the smart algo revolution? (Ad) I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before…
Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from.
Here’s why:
It does all the heavy lifting for you… automatically.
Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart! You’ll want to see what I’ve put on this page right here |
